Former in-house counsel at major pharma companies brings expertise in IP strategy, regulatory compliance, and business ...

Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer. The company said Wednesday that Garg will help oversee an integrated R&D organization to ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Investing.com -- Shares of Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) climbed 4% following the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommendation to ...

Alnylam Pharmaceuticals stands at a critical juncture, with the potential approval and launch of Amvuttra for ATTR-CM representing a significant growth opportunity.

Good day, everyone, and welcome to today's Alnylam Pharmaceuticals Q3 2024 Earnings ... in early onset Alzheimer's disease patients. In the chart here in the dotted line, you can see the rapid ...

Alnylam Pharmaceuticals Inc. has reached an impressive milestone, with its stock price soaring to an all-time high of $287.88. This peak reflects a significant surge in investor confidence ...

Fidelity Growth Strategies Fund highlighted stocks like Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the second quarter 2024 investor letter. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ...

Alnylam Pharmaceuticals ALNY reported second-quarter 2024 adjusted earnings of 56 cents per share against the Zacks Consensus Estimate of a loss of 74 cents. The improvement was primarily driven ...